Tigress Financial raised the firm's price target on Medline to $62 from $60 and keeps a Buy rating on the shares, arguing that the company's the ongoing transition from a traditional medical distributor to "a data-rich, AI-enabled supply chain partner" creates "near-term noise," but "a long-term buying opportunity."
